CathWorks announced that Mike Feher has joined CathWorks as Vice President of Finance and Chief Financial Officer. His appointment coincides with US commercialization of the CathWorks FFRangio™ System.
CathWorks announced the completion of a $30 million Series C financing round led by Deerfield Management.
CathWorks announced that Paul Kapsner has been named as Global Vice President of Sales. His appointment coincides with recent United States FDA clearance of the company’s CathWorks FFRangio™ System.
CathWorks announced today that its FFRangio™ System received United States Food & Drug Administration (FDA) 510(k) clearance. The FFRangio system demonstrated accuracy versus the invasive FFR wire in a blinded comparative study, FAST-FFR.
The journal Circulation published results from the CathWorks FFRangio™ FAST-FFR clinical trial in an article titled Accuracy of Fractional Flow Reserve Derived From Coronary Angiography.
The CathWorks FFRangio™ System will be featured in a TCT Lunch Presentation Theater Program held during the 2018 TCT (Transcatheter Cardiovascular Therapeutics) annual meeting in San Diego.
CathWorks announced that the FAST-FFR pivotal trial has been added to the late-breaking clinical science program during the 2018 TCT (Transcatheter Cardiovascular Therapeutics) annual meeting in San Diego.
CathWorks announced that it has submitted its CathWorks FFRangio™ System to the United States Food & Drug Administration (FDA) for review and 510(k) market clearance.
CathWorks announced that its FAST-FFR trial is fully enrolled ahead of schedule. The trial is designed to evaluate efficacy of the CathWorks FFRangio™ System in terms of sensitivity and specificity when compared to conventional invasive Fractional Flow Reserve (FFR).
CathWorks announced the approval of a new CPT code 0523T for non-invasive, 3D FFRangio™ enabled interpretation of possible atherosclerotic stenosis during coronary angiography interventions.